Geneva, Switzerland, June 25, 2020–7:30 amCEST –GeNeuro (Euronext Paris: CH0308403085 -GNRO), a biopharmaceutical company focused on stopping causal factors driving the progression of neurodegenerative and autoimmune diseasessuch as multiple sclerosis (MS)andamyotrophic lateral sclerosis (ALS), today announcesthe inclusion of thefirst patient in its Phase 2 trial of temelimab in MSat the Karolinska Institutet’s Academic Specialist Center (ASC), in Stockholm, Sweden.

For more information,